Roche hoping to gain edge with new diabetes-testing product
Roche Group is rolling out a new blood-glucose meter and a savings program for test strips, which it says it will make diabetes care more affordable.
Diabetes
Articles
Lilly diabetes drug Jardiance falls short of quarterly sales predictions
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
Local Roche units sue pharmacies over alleged test-strip scheme
Two Indianapolis-based subsidiaries of Swiss pharmaceutical giant Roche Group are accusing a group of pharmacies and supply houses of engaging in an elaborate scheme to defraud Roche of millions of dollars worth of sales on diabetes test strips.
UPDATE: Lilly to invest $85M in Indy as part of diabetes expansion
The expansion at the Lilly Technology Center southwest of downtown is part of an $850 million investment the company is making this year in its U.S. research labs, manufacturing plants and other operations.
Lilly to sell insulin at 40 percent discount to cash-paying patients
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
Lilly threatens Sanofi’s dominance in insulin with knockoff drug
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
After rough November, some good news for Lilly
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
Lilly competitor to cap price increases as drug costs face more scrutiny
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Lilly pledges $90 million to improve global drug access
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.
Lilly stock rises after FDA panel backs new Jardiance label
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
Merck, Pfizer double size of diabetes drug study to catch rivals
The competition heated up in the $71.5 billion global diabetes market last year after Indianapolis-based Eli Lilly’s and Boehringer Ingelheim’s Jardiance unexpectedly reduced the risk of heart attacks, strokes and deaths in a study.
Biochemist Richard DiMarchi is ‘true entrepreneur’
Biochemist has founded or co-founded five startups since retiring from Eli Lilly and Co. as head of biotechnology research 13 years ago, at age 50.
Insulin’s surging price turns diabetes staple into luxury good
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
Time to cheer on the struggling YMCA
The national not-for-profit organization, trying to fight back against high-end gyms and boutique studios, is now a national model for diabetes prevention.
Eli Lilly ends development of promising insulin drug
Eli Lilly said Friday that it decided to stop developing the insulin peglispro after learning that it would take more time and cost more than expected to understand a significant side effect.
SMARTT: Health disparities among Amos’ many causes
Before his untimely death, Amos Brown used his media pulpit to raise awareness among minority populations about their elevated risks of heart disease, diabetes and stroke.
Lilly competitor fails to win FDA backing for diabetes treatment
AstraZeneca Plc didn’t receive U.S. approval for a new diabetes treatment that combines two of its existing drugs. The combination would have competed with Glyxambi from Lilly.
Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
Lilly’s heart study sets up showdown with Novo’s Victoza
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Jardiance study lifts Lilly shares to 15-year high
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.